Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases-Reference-Cited by-同舟云学术

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases

Published:2023-07-21 Issue:15 Volume:66 Page:10824-10848
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Zhijie¹,Yin Li²,Xiong Zhenghan²,Huang Fei¹,Yang Na¹,Jiang Fei¹,Li Huili¹,Cui Yong¹,Ren Jiwei¹,Cheng Zitian¹,Jia Kun¹,Lu Tao¹³,Zhu Jiapeng⁴^ORCID,Hu Qinghua²^ORCID,Chen Yadong¹^ORCID

Affiliation:

1. School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China

2. School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China

3. State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China

4. School of Medicine and Life Sciences, State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China

Funder

China Pharmaceutical University

Natural Science Foundation of Jiangsu Province

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01028

Reference59 articles.

1. Biological and clinical significance of T helper 17 cell plasticity